Last reviewed · How we verify
Gemcitabine - 28 day cycle
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha
Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha Used for Pancreatic cancer, Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Gemcitabine - 28 day cycle |
|---|---|
| Also known as | Gemzar |
| Sponsor | Actuate Therapeutics Inc. |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase, DNA polymerase alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a nucleoside analog that is phosphorylated to its active diphosphate and triphosphate metabolites, which then inhibit ribonucleotide reductase and DNA polymerase alpha, resulting in the inhibition of DNA synthesis.
Approved indications
- Pancreatic cancer
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |